Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
Open Access
- 20 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (10), 2792-2797
- https://doi.org/10.1158/1078-0432.ccr-20-3761
Abstract
Purpose:. Cyclin and MAPK/MEK-related gene alterations are implicated in cell-cycle progression and cancer growth. Yet, monotherapy to target theOther Versions
Funding Information
- NCI (P30 CA023100)
- NIH (K08CA168999, R21CA192072)
This publication has 38 references indexed in Scilit:
- Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancerCancer Biology & Therapy, 2013
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaClinical Cancer Research, 2013
- MEK drives cyclin D1 hyperelevation during geroconversionCell Death & Differentiation, 2013
- Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neuronsMolecular Biology of the Cell, 2012
- Cyclin D as a therapeutic target in cancerNature Reviews Cancer, 2011
- Cyclin-Dependent Kinase Pathways As Targets for Cancer TreatmentJournal of Clinical Oncology, 2006
- Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomasOncogene, 2000
- G1 Cyclins and Control of the Cell Division Cycle in Normal and Transformed CellsCancer Investigation, 1997
- The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinasesCell, 1993
- Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage divisionCell, 1983